Kezar Life Sciences Appoints New Principal Accounting Officer
Jefferies Maintains Kezar Life Sciences(KZR.US) With Buy Rating, Cuts Target Price to $18
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
Kezar Life Sciences Price Target Lowered to $7 From $9 at Wells Fargo
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)
Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences
Kezar Drops After Q4 Results and Mid-stage Data for Lead Asset
Kezar Life Sciences Reports Topline Results From PORTOLA Trial
William Blair Maintains Kezar Life Sciences(KZR.US) With Buy Rating
William Blair Sticks to Their Buy Rating for Kezar Life Sciences (KZR)
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
KEZAR LIFE SCIENCES Earnings Results: $KZR Reports Quarterly Earnings
Kezar Life Sciences | 10-K: FY2024 Annual Report
Kezar Life Sciences | 8-K: Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End ...
Express News | Kezar Life Sciences Inc - Favorable Safety Profile Observed During 6-Month Treatment Period
Express News | Kezar Life Sciences Inc - Zetomipzomib Results in Steroid-Sparing Biochemical Remissions in Refractory Aih Patients
Express News | Kezar Life Sciences Announces Positive Topline Results From the Portola Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients With Autoimmune Hepatitis (Aih) and Reports Fourth Quarter and Year End 2024 Financial Results
Press Release: Kezar Life Sciences Announces Positive Topline Results From the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients With Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
Kezar Life Sciences 4Q Loss $20.2M >KZR
Kezar Life Sciences 4Q Loss/Shr $2.77 >KZR